ESR1 and breast cancer: In a pioneering study, Li et al.10 observed that when MCF7 cells (ERα+ breast cancer cell line) are treated with estrogen, thus activating ERα, of all the ERα-bound genomic regions with the active enhancer mark H3K27Ac, only a subset are transcribed (eRNAs).